“Predatory open-access publishing is an exploitative open-access academic publishing business model that involves charging publication fees to authors without providing the editorial and publishing services associated with legitimate journals (open access or not). The idea that they are “predatory” is based on the view that academics are tricked into publishing with them, though some authors may be aware that the journal is poor quality or even fraudulent.”
“On 25 August 2016, the Federal Trade Commission (FTC) filed a lawsuit against the OMICS Group, iMedPub, Conference Series, and the individual Srinubabu Gedela, an Indian national who is president of the companies. In the lawsuit, the defendants are accused of “deceiving academics and researchers about the nature of its publications and hiding publication fees ranging from hundreds to thousands of dollars”. The FTC was also responding to pressure to take action against predatory publishers.”
Examples of press releases promoting Fake Conferences and Predatory Publications:
Neurology today by Conference Series: Enlightening the new scope in the field of Neurology
SINGAPORE, LONDON (PRWEB) OCTOBER 27, 2018 – Conference Series is effectively providing a helping hand to spread awareness in the field of neurology by joining hands with neurology societies. The Neurology conferences of the Conference Series aim to provide the latest information in neurology and healthcare by organizing medical and healthcare meetings across America, Europe and Asia in collaboration with 1000+ scientific societies.
The Conference Series holds its own unique meetings, events, exhibitions and rank among the world’s leading medical event organizers. It organizes different events in domains like Medical, Pharmaceutical, Engineering, Science, Technology and Business. The Conference Series has 50 million+ visitors, 25000+ unique visitors per conference and 75000+ page views. Participation in any of the conferences hosted by the Conference Series gives a platform to network and to get accessibility to the various online communities and get worldwide recognition.
Dr. Srinubabu Gedela, CEO of Omics International observed “Neurology conferences are a remarkable event, which bring together a unique international mix of large and medium medical and clinical research and diagnostic companies. He dubbed these conferences as a perfect platform to share experience, foster collaborations across industry and academia.”
Neurology today holds a root position in the various medical centers of the world. The study of neurology therefore has immense scope in today’s world. Many neurologists are taking additional training or interest in areas of neurology, such as stroke, epilepsy, neuromuscular, sleep medicine, pain management, or movement disorders. Neurology conferences aim to bring together all these experts in order to provide them with an opportunity to share and discuss the latest research focused at spreading awareness regarding the various neurological conditions.
Neurology represent the largest and untapped market in medicine sector as per the current estimated market analysis report which is based on the probability of approval and sales of products in late stage development, demographic trends and selling of product. Emerging markets once again help to boost revenues. CNS therapeutics comprise approximately 15% of the total pharmaceutical sales, nearly $30 billion worldwide. The estimated annual economic cost of anxiety disorders, depression, and schizophrenia is $47 billion, $44 billion, and $33 billion, respectively.
The Neurology conferences of the Conference Series aim to keep up their position in the scientific milieu by hosting a variety of neurology related conferences in 2019 directed towards fomenting further advances in neurology.
An Attempt at Evaluating Whether the Open-Access Movement Has Erased the Boundaries in Neurology Research and Made It More Inclusive
SINGAPORE, LONDON (PRWEB) OCTOBER 27, 2018
International Open Access Week (October 22-28, 2018), is an important yearly event that aims to build awareness about the open access movement, which is an invaluable attempt to connect the global scientific community, and frees it from the customary membership model of scholastic distributing. Open Access Week serves as a portal for all academics the open access network come together to keep this force moving. This year’s theme- “designing equitable foundations for open knowledge,” is an attempt at evaluating whether the open access movement has fulfilled its commitment of bringing inclusivity to the field of scientific research.
Omics International is pleased to announce the celebration of the Open Access Week; researchers, academics, and clinicians are invited to come forward and share their opinions and findings in the field of neurology.
Neurology deals with the anatomy, functions, disorders and diseases of the nervous system. In view of the ever increasing age of the population, more and more people will be affected by age-related neurologic disorders, such as Alzheimer’s disease, Parkinson’s disease, and stroke. In the near future, diagnostic testing would hold the center stage in clinical neurology and would grow by leaps and bounds. It is likely that the field of Neurology is going to see an explosive growth in potential interventions, including novel drugs, immunosuppressant modalities, gene therapies, and human pluripotent stem cell technology in the near future.
This explosive growth cannot simply rely on the rapid turnover of articles; it needs to be buttressed by increased public engagement and visibility amongst the scientific community, all of which are guaranteed by the open-access format of publishing. Articles published in open-access journals are not only downloaded more, but also experience a more sustained number of downloads. Global science, technology, and medicine (STM) publishing is a $10 billion industry, whose market leaders enjoy double-digit profit margins; the open-access movement aims to shift the scales towards a more reader-friendly format.
Omics publishes some of the best Neurology journals, which showcase some of the most noteworthy articles in the field. These journals cover various aspects of neurology, such as neuro-physiology, neuro-imaging, neuro-pathology, clinical neurology, cognitive neuroscience, neuro-psychology, neuro-ethics, neurorehabilitation, neurological disorders, neuro-endocrinology, neuro-epidemiology, neuro-genetics, neuro-immunology, neuro-pharmacology, neuro-radiology, neuro-surgery, neuro-oncology, neurotoxicology, restorative neurology, neuro-morphology, neuroinfectious diseases etc.
The articles published in these journals not only encapsulate the latest trends in Neurology, but also cover a broad-spectrum of neurological research ranging from basic to applied research and from clinical research to mathematical, computational, and experimental approaches. Neurology open access journals serve as an efficient efficient platform to build upon the existing research and discoveries in the field of neurology.
Omics International has entered into spirit of the Open Access Week with gusto and has planned several activities for its authors, reviewers, Editors, and readers. Dr. Srinubabu Gedela, CEO Pulsus and Omics, has announced special benefits during this week.
Publishing an article in any of the Neurology open access journals during the Open Access week would be indicative of the solidarity of the authors with the open-access movement. It would be a very good opportunity for authors who wish to try out the open access publishing format for the first time.
Bringing the Best of Pharmaceutical Sciences to a Wider Audience by Participating in the Open Access Week
SINGAPORE, LONDON (PRWEB) OCTOBER 27, 2018
Omics International, the flag-bearer of the open access movement, is all set to commemorate the 10th International Open Access Week (October 22-28, 2018). Dr. Srinubabu Gedela, the Founder and CEO of Omics, has announced special recognition for manuscripts submitted during this period.
This year’s theme- “designing equitable foundations for open knowledge,” is an attempt at evaluating whether the open access movement has fulfilled its commitment of bringing inclusivity to the field of scientific research and identifying whether this movement has inadvertently brought about any inequities, and if yes, then how to contain and rectify these inequities.
Pharmaceutical science is a key branch of life science, aimed at improving the health statistics by aiding in the development of new therapeutic modalities and modification of the existing ones. Pharmaceutical research plays a singular role in developing new therapeutics and vaccines to prevent and manage diseases. Pharmaceutical progress has resulted in a dramatic decline in the mortality rates for diseases such as cancer, HIV/AIDS, and measles, thereby contributing to the prosperity of the society as a whole.
The global pharmaceutical drug market is estimated to reach USD 1.12 trillion in 2022. Currently, the North American pharmaceutical market is the largest in the world, and is worth USD 341.1 billion.
As pharmaceuticals represent such an essential component of public health, free access to pharmaceutical research is very important. When pharmaceutical companies are requesting for a governmental certification stating that their products are suitable for public consumption, the public requires these companies to openly disclose their research, even if doing so would end up undermining the profits of these pharmaceutical companies. Without access to such research, the public won’t know if these pharmaceutical products are fit for use. The plus-points of open-access publishing format such as faster impact, greater public engagement, and wider collaboration, are all the need of the hour in the present pharmaceutical scenario, what with the world being riddled with emergent infections and enhanced chronic illnesses such as diabetes, cancer, and mental health disorders. This year’s theme for the Open Access Week is an attempt at highlighting the tough questions in the field as it attempts to become more transparent and more morally and socially responsible.
Omics International has a significant footprint in the field of pharmaceutical research, with 62 pharmaceutical science journals being published under its masthead; these include reputed journals like: the International Journal of Drug Development & Research, Pharmaceutica Analytica Acta, the Journal of Bioequivalence & Bioavailability, the Journal of Biomolecular Research & Therapeutics, and Pharmaceutical Regulatory Affairs: Open Access. These journals are dedicated to publishing breakthroughs in the field and making them available to the largest possible readership, free of cost.
Entering into the spirit of the Open Access Week, Omics International has planned several activities for its authors, reviewers, Editors, and readers. Publishing an article in any of the journal issues during the Open Access Week would directly signal the solidarity of the authors with the open-access movement.
All the Editors, authors and reviewers are requested to participate in the open access week and share their experiences with everyone, thereby making their own indelible contribution to the open access movement.